3TZM

TGF-beta Receptor type 1 in complex with SB431542

Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.70 Å
  • R-Value Free: 0.205 
  • R-Value Work: 0.170 
  • R-Value Observed: 0.172 

wwPDB Validation   3D Report Full Report



Literature

Structural Basis for Specificity of TGFbeta Family Receptor Small Molecule Inhibitors

Ogunjimi, A.A., Zeqiraj, E., Ceccarelli, D.F., Sicheri, F., Wrana, J.L., David, L.

(2012) Cell Signal 24: 476-483

  • DOI: 10.1016/j.cellsig.2011.09.027
  • Primary Citation of Related Structures:  
    3TZM

  • PubMed Abstract: 

    • Transforming growth factor-β (TGFβ) receptor kinase inhibitors have a great therapeutic potential. SB431542 is one of the mainly used kinase inhibitors of the TGFβ/Activin pathway receptors, but needs improvement of its EC(50) (EC(50)=1 μM) to be transla ...

    Transforming growth factor-β (TGFβ) receptor kinase inhibitors have a great therapeutic potential. SB431542 is one of the mainly used kinase inhibitors of the TGFβ/Activin pathway receptors, but needs improvement of its EC(50) (EC(50)=1 μM) to be translated to clinical use. A key feature of SB431542 is that it specifically targets receptors from the TGFβ/Activin pathway but not the closely related receptors from the bone morphogenic proteins (BMP) pathway. To understand the mechanisms of this selectivity, we solved the crystal structure of the TGFβ type I receptor (TβRI) kinase domain in complex with SB431542. We mutated TβRI residues coordinating SB431542 to their counterparts in activin-receptor like kinase 2 (ALK2), a BMP receptor kinase, and tested the kinase activity of mutated TβRI. We discovered that a Ser280Thr mutation yielded a TβRI variant that was resistant to SB431542 inhibition. Furthermore, the corresponding Thr283Ser mutation in ALK2 yielded a BMP receptor sensitive to SB431542. This demonstrated that Ser280 is the key determinant of selectivity for SB431542. This work provides a framework for optimising the SB431542 scaffold to more potent and selective inhibitors of the TGFβ/Activin pathway.

    Organizational Affiliation: 

    Center for Systems Biology, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.



Macromolecules
Find similar proteins by: 
(by identity cutoff)  |  Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
TGF-beta receptor type-1 A309Homo sapiensMutation(s): 0 
Gene Names: TGFBR1, ALK5, SKR4
EC: 2.7.11.30
Find proteins for P36897 (Homo sapiens)
Explore P36897 
Go to UniProtKB:  P36897
NIH Common Fund Data Resources
PHAROS:  P36897
GTEx:  ENSG00000106799
Protein Feature View
Expand
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
085
Query on 085
Download Ideal Coordinates CCD File 
A
4-[5-(1,3-benzodioxol-5-yl)-4-(pyridin-2-yl)-1H-imidazol-2-yl]benzamide
C22 H16 N4 O3
FHYUGAJXYORMHI-UHFFFAOYSA-N		 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
085Ki:  17   nM  BindingDB
085IC50:  1542   nM  BindingDB
085EC50:  172   nM  BindingDB
085IC50:  94   nM  BindingDB
085IC50:  350   nM  BindingDB
085Kd:  190   nM  BindingDB
85Ki :  17   nM  PDBBind
085IC50:  66   nM  BindingDB
085IC50:  125   nM  BindingDB
085IC50:  250   nM  BindingDB
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.70 Å
  • R-Value Free: 0.205 
  • R-Value Work: 0.170 
  • R-Value Observed: 0.172 
  • Space Group: P 21 21 21
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 41.771α = 90
b = 77.726β = 90
c = 90.07γ = 90
Software Package:
Software NamePurpose
ADSCdata collection
MOLREPphasing
REFMACrefinement
HKL-2000data reduction
SCALEPACKdata scaling

Structure Validation

View Full Validation Report


View more in-depth experimental data

Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2012-05-23
    Type: Initial release